BioLineRx Ltd. (BLRX)

Last Price: 1.73 (2020-07-01)

Company Description

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-25.45M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.45
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -72.61%
Return on Assets (Trailing 12 Months) -47.17%
Current Ratio (Most Recent Fiscal Quarter) 1.88
Quick Ratio (Most Recent Fiscal Quarter) 1.88
Debt to Common Equity (Most Recent Fiscal Quarter) 0.24
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $4.46
Earnings per Share (Most Recent Fiscal Quarter) $-0.60
Earnings per Share (Most Recent Fiscal Year) $-2.55
Diluted Earnings per Share (Trailing 12 Months) $-2.01
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 7.48M
Free Float 7.40M
Market Capitalization $12.79M
Average Volume (Last 20 Days) 0.64M
Beta (Past 60 Months) 1.91
Percentage Held By Insiders (Latest Annual Proxy Report) 1.10%
Percentage Held By Institutions (Latest 13F Reports) 37.05%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%